MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Ovarian cancer diagnosis and treatment
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,301 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,301 works in the cohort · of 4,299,418page 24 of 47

Labels cover 7 of 2,301 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,301 of 2,301 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

fundno affunlabeled
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
Jacek Glajzer, Dan Cacsire Castillo‐Tong, Rolf Richter, Ignace Vergote, Hagen Kulbe, Adriaan Vanderstichele +14 more
2022· article· en· Annals of Surgical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affunlabeled
Ovarian Signet-ring Stromal Tumor
Naïri Tchrakian, Esther Oliva, Anne‐Sophie Chong, Barbara Rivera-Polo, Jennifer A. Bennett, Marisa R. Nucci +7 more
2022· article· en· The American Journal of Surgical Pathology· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affunlabeled
The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.
Bradley J. Monk, Rachel N. Grisham, Christian Marth, Susana Banerjee, Felix Hilpert, Robert L. Coleman +11 more
2015· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affno abstractunlabeled
MRI of gynecological neoplasm
Margaret H. Pui, Qiu Yan Wang, Bin Xu, Guo Ping Fan
2004· article· en· Clinical Imaging· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affno abstractunlabeled
Ovarian Cancer
Evis Sala, Nandita M. deSouza, Susanna I. Lee, Mostafa Atri, Hedvig Hricak
2010· review· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
7
citations

How this was built: Screen · Findings · About